טוען...
EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer
After the discovery of activating mutations in EGFR, EGFR tyrosine kinase inhibitors (TKIs) have been introduced into the first-line treatment of non-small-cell lung cancer (NSCLC). A series of studies have shown that EGFR TKI monotherapy as first-line treatment can benefit NSCLC patients harbouring...
שמור ב:
| הוצא לאור ב: | Oncotarget |
|---|---|
| Main Authors: | , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Impact Journals LLC
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5650459/ https://ncbi.nlm.nih.gov/pubmed/29088904 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.20095 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|